vTv Therapeutics (NASDAQ:VTVT) Raised to “Hold” at Zacks Research

vTv Therapeutics (NASDAQ:VTVT) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

VTVT has been the subject of a number of other reports. Wall Street Zen downgraded shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings cut vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. HC Wainwright lowered their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Lifesci Capital raised vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. Finally, BTIG Research upped their price objective on vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, vTv Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Trading Down 1.7%

Shares of VTVT opened at $32.79 on Monday. vTv Therapeutics has a 12-month low of $18.77 and a 12-month high of $44.00. The company has a market cap of $129.19 million, a PE ratio of -30.93 and a beta of 0.29. The stock has a 50-day moving average price of $32.86 and a 200-day moving average price of $34.51.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current year.

Hedge Funds Weigh In On vTv Therapeutics

A number of large investors have recently added to or reduced their stakes in VTVT. Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics during the fourth quarter valued at about $221,000. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics in the 4th quarter valued at about $731,000. Finally, Geode Capital Management LLC lifted its stake in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.